Evidence map›Paper›PMID 33618281›Full record

ArticleJournal of critical care2021

A preliminary cost-effectiveness analysis of lung protective ventilation with extra corporeal carbon dioxide removal (ECCO

Oliver Ethgen, Jacques Goldstein, Kai Harenski, Armand Mekontso Dessap, Philippe Morimont, Michael Quintel, Alain Combes

Open access · greenAbstract read
In one paragraph

Article in Journal of critical care, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 4 countries.

Oliver EthgenSERFAN Innovation, Namur, Belgium; Department of Public Health, Epidemiology & Health Economics, University of Liège, Liège, Belgium. Electronic address: o.ethgen@uliege.be.
Jacques GoldsteinBaxter World Trade SPRL, Braine l'Alleud, Belgium.
Kai HarenskiBaxter Healthcare Corporation, Deerfield, IL, USA.
Armand Mekontso DessapUPEC, Institut Mondor de Recherche Biomédicale, Groupe de Recherche Clinique CARMAS, Créteil F-94010, France; APHP, Hôpitaux Universitaires Henri Mondor, Service de Médecine Intensive Réanimation, Créteil F-94010, France.
Philippe MorimontGIGA-Laboratory of Critical Care Basic Sciences, University of Liège, Liège, Belgium.
Michael QuintelDepartment of Anaesthesia and Intensive Care Medicine, University of Göttingen Medical Center Von-Siebold-Straße 3, 37075 Göttingen, Germany.
Alain CombesSorbonne Université, INSERM, UMRS_1166-ICAN, Institute of Cardio Metabolism and Nutrition, F-75013 Paris, France; Service de Médecine Intensive-Réanimation, Institut de Cardiologie, APHP Hôpital Pitié-Salpêtrière, F-75013 Paris, France.
University of Liège · BEBaxter (Belgium) · BEBaxter (United States) · USHôpitaux Universitaires Henri-Mondor · FRInserm · FRUniversity of Göttingen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMechanical ventilation (MV) is the cornerstone in the management of the acute respiratory distress syndrome (ARDS). Recent research suggests that decreasing the intensity of MV using lung protective ventilation (LPV) with lower tidal volume (Vt) and driving pressure (∆P) could improve survival. Extra-corporal CO

methodsWe modelled the distribution over time of ventilated ARDS patients across 3 health-states (alive & ventilated, alive & weaned from ventilation, dead). We compared the outcomes of 3 strategies: MV (no ECCO

resultsBoth LPV and ULPV as enabled by ECCO2R provided favorable results at Day 60 as compared to MV. Survival rates were increased with the protective strategies, notably with ULPV that provided even more manifest benefits as compared to MV. LPV and ULPV produced +0.162 and + 0.627 incremental QALYs as compared to MV, respectively. LPV and ULPV costs were augmented because of their survival benefits. Nonetheless, ICERs of LPV and ULPV vs. MV were all well below the €50,000 threshold. ULPV also presented with favorable ICERs as compared to LPV (i.e. less than €25,000/QALY).

conclusionsECCO

Indexed as

Carbon DioxideRespiratory Distress SyndromeCost-Benefit AnalysisHumansLungRespiration, ArtificialCarbon DioxideAcute respiratory distress syndrome (ARDS)Cost-effectivenessExtra corporeal carbon dioxide removal (ECCO2R)Lung protective ventilation

Identifiers

PMID33618281
PMCPMC7972812
OpenAlexW3127931899

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.